Jacqueline A French1, Andrew J Cole1, Edward Faught1, William H Theodore1, Annamaria Vezzani1, Kore Liow1, Jonathan J Halford1, Robert Armstrong1, Jerzy P Szaflarski1, Sarah Hubbard1, Jagdish Patel1, Kun Chen1, Wei Feng1, Marco Rizzo2, Jacob Elkins1, Gabrielle Knafler1, Kimberly A Parkerson1. 1. From the NYU Grossman School of Medicine (J.A.F.), New York, NY; Massachusetts General Hospital (A.J.C.), Boston; Emory University School of Medicine (E.F.), Atlanta, GA; National Institutes of Health (W.H.T.), Bethesda, MD; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri (A.V.), Milan, Italy; Hawaii Pacific Neuroscience (K.L.), Honolulu; Medical University of South Carolina (J.J.H.), Charleston; Asheville Neurology Specialists (R.A.), NC; University of Alabama at Birmingham (J.P.S.); Biogen (S.H., J.P., W.F., M.R.), Cambridge; Alexion (K.C.), Boston; Sarepta (J.E.), Cambridge; Envision Pharma Group (G.K.), Fairfield, CT; and Stoke Therapeutics (K.A.P.), Bedford, MA. K.C., J.E., and K.A.P. were affiliated with Biogen, Cambridge, MA, at the time of the study. 2. From the NYU Grossman School of Medicine (J.A.F.), New York, NY; Massachusetts General Hospital (A.J.C.), Boston; Emory University School of Medicine (E.F.), Atlanta, GA; National Institutes of Health (W.H.T.), Bethesda, MD; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri (A.V.), Milan, Italy; Hawaii Pacific Neuroscience (K.L.), Honolulu; Medical University of South Carolina (J.J.H.), Charleston; Asheville Neurology Specialists (R.A.), NC; University of Alabama at Birmingham (J.P.S.); Biogen (S.H., J.P., W.F., M.R.), Cambridge; Alexion (K.C.), Boston; Sarepta (J.E.), Cambridge; Envision Pharma Group (G.K.), Fairfield, CT; and Stoke Therapeutics (K.A.P.), Bedford, MA. K.C., J.E., and K.A.P. were affiliated with Biogen, Cambridge, MA, at the time of the study. marco.rizzo@biogen.com.
Abstract
BACKGROUND AND OBJECTIVES: To explore efficacy/safety of natalizumab, a humanized monoclonal anti-α4-integrin antibody, as adjunctive therapy in adults with drug-resistant focal epilepsy. METHODS: Participants with ≥6 seizures during the 6-week baseline period were randomized 1:1 to receive natalizumab 300 mg IV or placebo every 4 weeks for 24 weeks. Primary efficacy outcome was change from baseline in log-transformed seizure frequency, with a predefined threshold for therapeutic success of 31% relative reduction in seizure frequency over the placebo group. Countable seizure types were focal aware with motor signs, focal impaired awareness, and focal to bilateral tonic-clonic. Secondary efficacy endpoints/safety were also assessed. RESULTS: Of 32 and 34 participants dosed in the natalizumab 300 mg and placebo groups, 30 (94%) and 31 (91%) completed the placebo-controlled treatment period, respectively (one participant was randomized to receive natalizumab but not dosed due to IV complications). Estimated relative change in seizure frequency of natalizumab over placebo was -14.4% (95% confidence interval [CI] -46.1%-36.1%; p = 0.51). The proportion of participants with ≥50% reduction from baseline in seizure frequency was 31.3% for natalizumab and 17.6% for placebo (odds ratio 2.09, 95% CI 0.64-6.85; p = 0.22). Adverse events were reported in 24 (75%) and 22 (65%) participants receiving natalizumab vs placebo. DISCUSSION: Although the threshold to demonstrate efficacy was not met, there were no unexpected safety findings and further exploration of possible anti-inflammatory therapies for drug-resistant epilepsy is warranted. TRIAL REGISTRATION INFORMATION: The ClinicalTrials.gov registration number is NCT03283371. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that IV natalizumab every 4 weeks, compared to placebo, did not significantly change seizure frequency in adults with drug-resistant epilepsy. The study lacked the precision to exclude an important effect of natalizumab.
BACKGROUND AND OBJECTIVES: To explore efficacy/safety of natalizumab, a humanized monoclonal anti-α4-integrin antibody, as adjunctive therapy in adults with drug-resistant focal epilepsy. METHODS: Participants with ≥6 seizures during the 6-week baseline period were randomized 1:1 to receive natalizumab 300 mg IV or placebo every 4 weeks for 24 weeks. Primary efficacy outcome was change from baseline in log-transformed seizure frequency, with a predefined threshold for therapeutic success of 31% relative reduction in seizure frequency over the placebo group. Countable seizure types were focal aware with motor signs, focal impaired awareness, and focal to bilateral tonic-clonic. Secondary efficacy endpoints/safety were also assessed. RESULTS: Of 32 and 34 participants dosed in the natalizumab 300 mg and placebo groups, 30 (94%) and 31 (91%) completed the placebo-controlled treatment period, respectively (one participant was randomized to receive natalizumab but not dosed due to IV complications). Estimated relative change in seizure frequency of natalizumab over placebo was -14.4% (95% confidence interval [CI] -46.1%-36.1%; p = 0.51). The proportion of participants with ≥50% reduction from baseline in seizure frequency was 31.3% for natalizumab and 17.6% for placebo (odds ratio 2.09, 95% CI 0.64-6.85; p = 0.22). Adverse events were reported in 24 (75%) and 22 (65%) participants receiving natalizumab vs placebo. DISCUSSION: Although the threshold to demonstrate efficacy was not met, there were no unexpected safety findings and further exploration of possible anti-inflammatory therapies for drug-resistant epilepsy is warranted. TRIAL REGISTRATION INFORMATION: The ClinicalTrials.gov registration number is NCT03283371. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that IV natalizumab every 4 weeks, compared to placebo, did not significantly change seizure frequency in adults with drug-resistant epilepsy. The study lacked the precision to exclude an important effect of natalizumab.
Authors: Ingrid E Scheffer; Samuel Berkovic; Giuseppe Capovilla; Mary B Connolly; Jacqueline French; Laura Guilhoto; Edouard Hirsch; Satish Jain; Gary W Mathern; Solomon L Moshé; Douglas R Nordli; Emilio Perucca; Torbjörn Tomson; Samuel Wiebe; Yue-Hua Zhang; Sameer M Zuberi Journal: Epilepsia Date: 2017-03-08 Impact factor: 5.864
Authors: Leah P Dickstein; Jeih-San Liow; Alison Austermuehle; Sami Zoghbi; Sara K Inati; Kareem Zaghloul; Paolo Zanotti-Fregonara; William H Theodore Journal: Epilepsia Date: 2019-05-30 Impact factor: 5.864
Authors: Leah D Gershen; Paolo Zanotti-Fregonara; Irene H Dustin; Jeih-San Liow; Jussi Hirvonen; William C Kreisl; Kimberly J Jenko; Sara K Inati; Masahiro Fujita; Cheryl L Morse; Chad Brouwer; Jinsoo S Hong; Victor W Pike; Sami S Zoghbi; Robert B Innis; William H Theodore Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano Journal: Front Neurol Date: 2022-03-11 Impact factor: 4.003
Authors: María José Aguilar-Castillo; Pablo Cabezudo-García; Nicolas Lundahl Ciano-Petersen; Guillermina García-Martin; Marta Marín-Gracia; Guillermo Estivill-Torrús; Pedro Jesús Serrano-Castro Journal: Biomedicines Date: 2022-03-19